Specifically, the FGFR3 mutation rate was the highest in the NMIBC group (45.1%), followed by the MIBC (22.7%) and UTUC (14.3%) groups (Table 2). The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.